EMA – Page 14 – Pharma.Tips

ADME liabilities identified late during regulatory interaction preparation – risk mitigation strategy

Identifying Late-Stage ADME Liabilities in Regulatory Preparations: An Investigative Approach In the dynamic landscape of pharmaceutical research and drug development, encountering ADME (Absorption, Distribution, Metabolism, and Excretion) liabilities late in…

Target validation uncertainty during regulatory interaction preparation – impact on IND success probability

Addressing Target Validation Uncertainty in Regulatory Interaction Preparation to Enhance IND Success Probability Target validation is a critical phase in the drug discovery process, providing evidence that a therapeutic target…

Off-target toxicity signals during regulatory interaction preparation – data package strengthening approach

Addressing Off-target Toxicity Signals in Regulatory Interaction Preparation In the dynamic landscape of drug discovery, the identification of off-target toxicity signals can pose significant challenges, particularly during the critical regulatory…

Poor hit-to-lead progression during regulatory interaction preparation – data package strengthening approach

Poor Hit-to-Lead Progression: Addressing Challenges During Regulatory Preparation Poor hit-to-lead progression can pose significant challenges during the regulatory interaction preparation phase, affecting the overall success of drug development. As researchers…

ADME liabilities identified late during regulatory interaction preparation – decision framework regulators expect

Addressing ADME Liabilities Found Late in Regulatory Readiness: A Decision Framework In pharmaceutical development, ADME (Absorption, Distribution, Metabolism, and Excretion) liabilities uncovered during late-stage regulatory preparation can have significant repercussions.…

Poor hit-to-lead progression during translational assessment – how to avoid late-stage attrition

Addressing Poor Hit-to-Lead Progression During Translational Assessment to Mitigate Late-Stage Attrition In the evolving landscape of pharmaceutical research and drug development, poor hit-to-lead progression during translational assessment emerges as a…

Off-target toxicity signals during early discovery – decision framework regulators expect

Framework for Investigating Off-Target Toxicity Signals in Early Discovery Phases In the evolving landscape of pharmaceutical research, early identification of off-target toxicity signals is critical for the successful advancement of…

Target validation uncertainty during translational assessment – decision framework regulators expect

“`html Framework for Investigating Target Validation Uncertainty in Translational Assessment In the context of drug development, especially during the preclinical phase, target validation is critical yet complex. Investigating uncertainties that…

ADME liabilities identified late during portfolio review – decision framework regulators expect

“`html Framework for Addressing Late-Identified ADME Liabilities in Portfolio Reviews In the complex world of pharmaceutical development, identifying Absorption, Distribution, Metabolism, and Excretion (ADME) liabilities early in the drug discovery…

Off-target toxicity signals during regulatory interaction preparation – risk mitigation strategy

Risk Mitigation Strategies for Off-Target Toxicity Signals During Regulatory Interactions In the drug development lifecycle, preparation for regulatory interactions is pivotal. Indications of off-target toxicity during preclinical studies or interactions…

ADME liabilities identified late during regulatory interaction preparation – how to avoid late-stage attrition

Addressing Late Identification of ADME Liabilities During Regulatory Preparations In the landscape of pharmaceutical drug development, the late identification of ADME (Absorption, Distribution, Metabolism, and Excretion) liabilities can lead to…

Poor hit-to-lead progression during early discovery – risk mitigation strategy

“`html Strategic Investigation into Poor Hit-to-Lead Progression During Early Discovery In the highly competitive realm of pharmaceutical research and drug development, the ability to swiftly and effectively advance compounds from…